BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. Marquez-Rodas I, Dutriaux C, Saiag P, de la Cruz Merino L, et al. J Clin Oncol 2025 Jun 27:JCO2402595. doi: 10.1200/JCO-24-02595.

Read + Share

Amedeo Smart

Independent Medical Education

Marquez-Rodas I, Dutriaux C, Saiag P, de la Cruz Merino L, et al. BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. J Clin Oncol 2025 Jun 27:JCO2402595. doi: 10.1200/JCO-24-02595.
PMID: 40577656